Affordable Access

deepdyve-link
Publisher Website

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.

Authors
  • Boum, Yap1
  • Juan-Giner, Aitana2
  • Hitchings, Matt3
  • Soumah, Aboubacar2
  • Strecker, Thomas4
  • Sadjo, Mariama5
  • Cuthbertson, Hannah6
  • Hayes, Peter7
  • Tchaton, Marie2
  • Jemmy, Jean-Paul8
  • Clarck, Carolyn9
  • King, Deborah7
  • Faga, Elisabetta Maria8
  • Becker, Stephan4
  • Halis, Bassam6
  • Gunnstein, Norheim9
  • Carroll, Miles6
  • Røttingen, John-Arne10
  • Kondé, Mandy Kader11
  • Doumbia, Moise12
  • And 5 more
  • 1 Epicentre, Yaoundé, Cameroon. , (Cameroon)
  • 2 Epicentre, Paris, France. , (France)
  • 3 Center for Communicable Disease Dynamics and Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • 4 Institute of Virology, Philipps University, Marburg, Germany. , (Germany)
  • 5 Centre Hospital-Universitaire de Donka, Conakry, Guinea. , (Guinea)
  • 6 Public Health England, National Infection Service, Porton Down, UK.
  • 7 Division of Medicine, Department of Infectious Diseases, Imperial College London, UK.
  • 8 Médecins Sans Frontières-Operational Center Belgium, Brussels, Belgium. , (Belgium)
  • 9 Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway. , (Norway)
  • 10 Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway; Department of Health and Society, University of Oslo, Norway; Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA; Coalition for Epidemic Preparedness Innovations, Care of Norwegian Institute of Public Health, Oslo, Norway; Research Council of Norway, Oslo, Norway. , (Norway)
  • 11 Center of Excellence for Training, Research On Malaria & Priority Diseases In Guinea, Conakry, Guinea. , (Guinea)
  • 12 World Health Organization, Geneva, Switzerland. , (Switzerland)
  • 13 Epicentre, Paris, France. Electronic address: [email protected] , (France)
Type
Published Article
Journal
Vaccine
Publication Date
Jun 26, 2020
Volume
38
Issue
31
Pages
4877–4884
Identifiers
DOI: 10.1016/j.vaccine.2020.04.066
PMID: 32499066
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

As part of a Phase III trial with the Ebola vaccine rVSVΔG-ZEBOV-GP in Guinea, we invited frontline workers (FLWs) to participate in a sub-study to provide additional information on the immunogenicity of the vaccine. We conducted an open-label, non-randomized, single-arm immunogenicity evaluation of one dose of rVSVΔG-ZEBOV-GP among healthy FLWs in Guinea. FLWs who refused vaccination were offered to participate as a control group. We followed participants for 84 days with a subset followed-up for 180 days. The primary endpoint was immune response, as measured by ELISA for ZEBOV-glycoprotein-specific antibodies (ELISA-GP) at 28 days. We also conducted neutralization, whole virion ELISA and enzyme-linked immunospot (ELISPOT) assay for cellular response. A total of 1172 participants received one dose of vaccine and were followed-up for 84 days, among them 114 participants were followed-up for 180 days. Additionally, 99 participants were included in the control group and followed up for 180 days. Overall, 86.4% (95% CI 84.1-88.4) of vaccinated participants seroresponded at 28 days post-vaccination (ELISA- GP) with 65% of these seroresponding at 14 days post-vaccination. Among those who seroresponded at 28 days, 90.7% (95% CI 82.0-95.4) were still seropositive at 180 days. The proportion of seropositivity in the unvaccinated group was 0.0% (95% CI 0.0-3.8) at 28 days and 5.4% (95% CI 2.1-13.1) at 180 days post-vaccination. We found weak correlation between ELISA-GP and neutralization at baseline but significant pairwise correlation at 28 days post-vaccination. Among samples analysed for cellular response, only 1 (2.2%) exhibited responses towards the Zaire Ebola glycoprotein (Ebola GP ≥ 10) at baseline, 10 (13.5%) at day 28 post-vaccination and 27 (48.2%) at Day 180. We found one dose of rVSVΔG-ZEBOV-GP to be highly immunogenic at 28- and 180-days post vaccination among frontline workers in Guinea. We also found a cellular response that increased with time. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times